Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PPIB | P23284 | 1/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.44 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | PPIG | Q13427 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | YWHAG | P61981 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10899541 | 0.90 | CYP1A2 (0.61) | CYP1A2LMNACYP3A4TSHRCYP2C9 | |
| SCHEMBL11146009 | 0.87 | ALDH1A1 (0.63) | CYP1A2LMNACYP3A4TSHRCYP2C9 | |
| SCHEMBL85523 | 0.85 | PPID (0.58) | CYP1A2LMNACYP3A4TSHRALDH1A1 | |
| SCHEMBL13826445 | 0.84 | ALDH1A1 (0.48) | CYP3A4TSHRCYP2C19ALDH1A1GAA | |
| SCHEMBL1885468 | 0.84 | ALDH1A1 (0.58) | CYP1A2LMNATSHRCYP2C19ALDH1A1 | |
| SCHEMBL5542953 | 0.84 | ALDH1A1 (0.46) | CYP1A2LMNATSHRALDH1A1GAA | |
| SCHEMBL2400474 | 0.84 | KMT2A (0.51) | CYP1A2TSHRCYP2C9ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL77910 | 0.84 | PPIB (0.56) | CYP1A2LMNACYP3A4TSHRALDH1A1 | |
| SCHEMBL28010049 | 0.83 | TDP1 (0.56) | CYP1A2LMNACYP3A4TSHRCYP2C9 | |
| SCHEMBL13481189 | 0.82 | KLK7 (0.52) | ALDH1A1GAAMAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417285-B | Isomanka key intermediate and preparation method thereof | 苏中药业集团股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-117417285-A | Isomanka key intermediate and preparation method thereof | 苏中药业集团股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-9073905-B2 | Rock inhibitors | AMAKEM NV (BE) | 2015-07-07 | — | — | US | disclosed |
| US-9073905-B2 | Rock inhibitors | AMAKEM NV (BE) | 2015-07-07 | — | — | US | disclosed |
| WO-2015060359-A1 | NOVEL DIAMINE, POLYAMIC ACID, AND POLYIMIDE | 日産化学工業株式会社 | 2015-04-30 | — | — | WO | disclosed |
| US-20140057942-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057942-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2014-02-27 | — | — | US | disclosed |
| WO-2012146724-A2 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2012-11-01 | — | — | WO | disclosed |
| EP-0052296-B1 | GLUTAMINE DERIVATIVES USABLE FOR CURING IMMUNE DISEASES, METHODS FOR THEIR PREPARATION AND COMPOSITIONS COMPRISING SAID DERIVATIVES | MITSUBISHI KASEI CORPORATION (JP) | 1984-06-27 | — | — | EP | disclosed |
| US-4439448-A | IMMUNOMODULATING ACTIVITY | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1984-03-27 | — | — | US | disclosed |
| EP-0052296-A1 | Glutamine derivatives usable for curing immune diseases, methods for their preparation and compositions comprising said derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057942-A1 | NOVEL ROCK INHIBITORS | ROCK1, ROCK2, CIT | CYP1A2 636/4885LMNA 3808/4885CYP3A4 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.